Construction method and application of AKAP12 mutant gene knock-in animal model

The construction of the AKAP12 mutation gene knock-in animal model through CRISPR/Cas9 technology has solved the problem that it is difficult to establish a stable autism animal model in the existing technology, achieved efficient autism research and drug development, and provided new for autism diseases. research direction and clinical application.

CN118910044APending Publication Date: 2024-11-08WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410901028.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

It is difficult to establish a stable animal model that conforms to the clinical characteristics of autism, which is used to study the pathogenic mechanisms and drug development of autism.

Method used

Using CRISPR/Cas9 gene editing technology, a model of knock-in AKAP12 mutant genes was constructed by designing specific targeting AKAP12 mutant genes into animal models, including introducing Cas9 mRNA, homologous vector and sgRNA mixture into fertilized eggs, and screening was obtained. A stable inherited homozygous mutant animal model.

Benefits of technology

The constructed AKAP12 mutant gene knock-in animal model is efficient, controllable, repeatable, has good stability, and is in line with the clinical characteristics of autism. It is suitable for the research on pathogenic mechanisms and drug development of autism diseases, providing new Research direction and clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004930474700000071
    Figure BDA0004930474700000071
  • Figure HDA0004930474710000011
    Figure HDA0004930474710000011
  • Figure HDA0004930474710000012
    Figure HDA0004930474710000012
Patent Text Reader

Abstract

The invention discloses a construction method of an AKAP12 mutant gene knock-in animal model and application of the AKAP12 mutant gene knock-in animal model, and particularly discloses sgRNA of a specific target AKAP12 mutant gene, and the sequence of the sgRNA is GAGCTCTGCGTCGTCCCCCGAGAGG and GGTCTCTCCAGGCTCTGGGGGG. The invention further discloses a construction method of the AKAP12 mutant gene knock-in animal model and application of the AKAP12 mutant gene knock-in animal model. The mutation site of the AKAP12 mutant gene is c.1655 to 1659del, and the mutation site of the AKAP12 mutant gene is c.1655 to 1659del. According to the sgRNA provided by the invention, an AKAP12 mutant gene (c.1655-1659del) knock-in animal model can be constructed on the basis of a CRISPR / Cas9 gene editing technology, and the sgRNA is used for screening drugs for autism or researching the pathogenic mechanism of autism.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a method for constructing an AKAP12 mutant gene knock-in animal model and application thereof. Background Art

[0002] CRISPR / Cas9 (Clustered Regularly Interspaced Short PalindromicRepeats / CRISPR associated nuclease 9) gene editing technology is a technology that uses RNA to mediate the targeted modification of the target gene by the Cas9 protein. Cas9 is a CRISPR-related nuclease that contains two nuclease domains. Under the guidance of guide RNA, it can cut the two single-stranded DNA at the target gene site, causing double-strand breaks in the DNA and triggering cell-autonomous DNA damage repair. If an exogenous DNA fragment carrying a mutation is introduced into the cell at the same time, the cell can use this DNA fragment as a template for repair during autonomous DNA damage repair, thereby achieving site-specific knock-in of the target site, as well as various modifications such as gene correction.

[0003] CRISPR / Cas9 technology has a wide range of applications in bioengineering and biomedicine. It can quickly establish animal models and cell models of gene mutations to explore the relationship between genetic variation and disease.

[0004] Autism Spectrum Disorder (ASD), also known as autism, is a developmental disorder of the brain and nervous system with social interaction disorders, language communication disorders, narrow interests and repetitive stereotyped behaviors as the core clinical manifestations. The disease seriously affects the neuropsychiatric health of the child, and its pathogenic mechanism is still unclear. Therefore, how to establish a stable animal model that can better simulate the clinical characteristics of autism has become a technical problem that technicians in this field need to solve urgently. Summary of the invention

[0005] The purpose of the present invention is to provide a method and application of constructing an AKAP12 mutant gene knock-in animal model based on CRISPR / Cas9 technology, so as to provide an effective experimental animal model for the mechanism research of autism, drug development and efficacy evaluation.

[0006] The purpose of the first aspect of the present invention is to provide a sgRNA that specifically targets the AKAP12 mutant gene.

[0007] The second aspect of the present invention is a kit.

[0008] The purpose of the third aspect of the present invention is to provide the use of the sgRNA of the first aspect of the present invention or the kit of the second aspect of the present invention in constructing an AKAP12 mutant gene knock-in animal model.

[0009] The purpose of the fourth aspect of the present invention is to provide a method for constructing an AKAP12 mutant gene knock-in animal model based on CRISPR / Cas9 technology.

[0010] The purpose of the fifth aspect of the present invention is to provide the use of the AKAP12 mutant gene knock-in animal model of the fifth aspect of the present invention in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.

[0011] In order to achieve the above object, the technical solution adopted by the present invention is:

[0012] In a first aspect of the present invention, a sgRNA specifically targeting the AKAP12 gene is provided, wherein the sequence of the sgRNA comprises:

[0013] sgRNA1:GAGCTCTGCGTCGTCCCCCGAGG; and / or,

[0014] sgRNA2:GGTCTCCTCAGGCCTCGGGGG.

[0015] The second aspect of the present invention provides a kit, which comprises the sgRNA of the first aspect of the present invention.

[0016] In some embodiments of the present invention, the kit further comprises Cas9 mRNA and / or a homologous vector containing a mutation site, and the mutation site is c.1655-1659del.

[0017] In some embodiments of the present invention, the nucleotide sequence of the homologous vector containing the mutation site is shown as SEQ ID NO:3.

[0018] In some embodiments of the present invention, the kit further comprises amplification primers and sequencing primers.

[0019] In some embodiments of the present invention, the amplification primers include the primer pair shown in SEQ ID NO:4 and SEQ ID NO:5.

[0020] In some embodiments of the present invention, the sequence of the sequencing primer is shown in SEQ ID NO:6.

[0021] The third aspect of the present invention provides use of the sgRNA of the first aspect of the present invention or the kit of the second aspect of the present invention in constructing an animal model of AKAP12 gene mutation.

[0022] In some embodiments of the present invention, the animal model is one of a mouse, a rat, and a monkey.

[0023] In some preferred embodiments of the present invention, the animal model is a rat.

[0024] The fourth aspect of the present invention provides a method for constructing an AKAP12 gene mutation animal model based on CRISPR / Cas9 technology, the method comprising constructing the model using the kit of the second aspect of the present invention.

[0025] In some embodiments of the present invention, the method comprises: introducing a mixture of the Cas9 mRNA, the homologous vector containing the mutation site and the sgRNA into the fertilized egg of the model animal, obtaining a viable fertilized egg, transplanting it into a surrogate mother, breeding, obtaining offspring and performing genotype identification and screening to obtain a stable inherited homozygous mutant animal model.

[0026] In some embodiments of the present invention, in the mixture, the mass ratio of the Cas9 mRNA, the homologous vector containing the mutation site and the sgRNA is 1:0.5-1.5:0.5-1.5; the mass ratio of the sgRNA1 and sgRNA2 is 1:0.5-1.5.

[0027] In some embodiments of the present invention, in the mixture, the final concentrations of the Cas9 mRNA, the homologous vector containing the mutation site, and the sgRNA are all 100 to 300 ng / μL.

[0028] In some embodiments of the present invention, the method of introducing comprises injection.

[0029] In some embodiments of the present invention, the genotype identification and screening includes taking tail blood from offspring animals, amplifying and sequencing by PCR.

[0030] In some preferred embodiments of the present invention, the primers used in the PCR amplification include a primer pair of Rat AKAP12-F and Rat AKAP12-R, the base sequence of the primer Rat AKAP12-F is shown in SEQ ID NO:4, and the base sequence of the primer Rat AKAP12-R is shown in SEQ ID NO:5.

[0031] In some preferred embodiments of the present invention, the base sequence of the sequencing primer used in the sequencing process is shown in SEQ ID NO:6.

[0032] In some embodiments of the present invention, the viable fertilized eggs are transplanted into a surrogate mother and the offspring obtained by breeding are named F0 generation animal model; the positive F0 generation animal model obtained by genotype identification and screening is mated with the wild type to breed an F1 generation animal model; the F1 generation heterozygous animal model obtained by genotype identification and screening is hybridized to breed an F2 generation animal model, and the positive F2 generation homozygous animal model, i.e., the AKAP12 mutant gene knock-in animal model, is obtained by genotype identification and screening.

[0033] In some embodiments of the present invention, the animal model is one of a mouse, a rat, and a monkey.

[0034] In some preferred embodiments of the present invention, the animal model is a rat.

[0035] The fifth aspect of the present invention provides an application of a KAP12 mutant gene knock-in animal model constructed by the method for constructing an AKAP12 mutant gene knock-in animal model according to the fourth aspect of the present invention in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.

[0036] The beneficial effects of the present invention are:

[0037] The present invention is the first to find that the AKAP12 gene is mutated in the genome of children with autism, and the mutation site is c.1655-1659del. To this end, based on the mutation site, the present invention provides a sgRNA that specifically targets the AKAP12 mutant gene, through which the sgRNA can be constructed based on CRISPR / Cas9 gene editing technology to obtain an AKAP12 mutant gene (c.1655-1659del) knock-in animal model, which is the first successful construction of an AKAP12 mutant gene knock-in rat; the animal model has high knock-in efficiency, high controllability, good repeatability, and is easy to breed and raise, which makes up for the shortcomings of existing animal models, and is more stable and more in line with the clinical characteristics of autism; it is helpful for the study of the pathogenic mechanism of autism and the development of drugs for the treatment of autism, and can provide new research directions for related research on autism, and provide a good foundation for the pathogenesis and intervention research of autism. Using this animal model, it can provide more in-depth insights for related research on autism-related diseases; it has good medical clinical application prospects and wide utilization value. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The present invention uses CRISPR / Cas9 to construct an AKAP12 mutant gene knock-in rat autism animal model.

[0039] Figure 2This is the identification and sequencing map of the F0 generation AKAP12 gene mutation knock-in rat No. 26. The upper picture is the wild-type sequencing map, and the lower picture is the sequencing map of the F0 generation rat No. 26.

[0040] Figure 3 These are the results of ultrasonic vocalization in AKAP12 mutant gene knock-in rats separated from their mothers and pups, where WT: AKAP12 wild type, HO: AKAP12 mutant.

[0041] Figure 3 A is the total duration of vocalization after the pup was separated from the mother.

[0042] Figure 3 B is the number of vocalizations made by the pups after they were separated from their mothers.

[0043] Figure 3 C is a schematic diagram of the ultrasonic graph of the vocalization of the pup.

[0044] Figure 4 Results of social interaction in AKAP12 mutant gene knock-in rats.

[0045] Figure 4 A is a rat sociability test in the three-box experiment. Upper figure: thermal imaging of the interaction between the experimental rat and the stranger rat 1 (S1) and the empty box (E); lower figure: quantification of the interaction time between the experimental rat and the stranger rat 1 (S1) and the empty box (E).

[0046] Figure 4 B is a test of novelty preference of rats in the three-box experiment. Upper figure: thermal imaging of the interaction between the experimental rat and stranger rat 1 (S1) and stranger rat 2 (S2); lower figure: quantification of the interaction time between the experimental rat and stranger rat 1 (S1) and stranger rat 2 (S2).

[0047] Figure 4 C is the frequency of social interaction of the model mice, including the number of times the experimental mice sniffed, followed, and pushed the unfamiliar mice.

[0048] Figure 5 Identification of repetitive stereotypic behaviors in AKAP12 mutant gene knock-in rats.

[0049] Figure 5 A shows the bead burial situation of model mice.

[0050] Figure 5 B shows the grooming of the model mice when they were active in an open field.

[0051] Figure 6 The expression levels of Map2 at the mRNA and protein levels in the brain of rats with AKAP12 mutant gene knock-in.

[0052] Figure 6 A is the expression level of Map2 mRNA.

[0053] Figure 6 B is the quantification of Map2 protein expression.

[0054] Figure 6 C is the blotting of Map2 protein expression.

[0055] Figure 7 The PKA binding domain is lost after AKAP12 mutation.

[0056] Figure 7 A is a schematic diagram of the protein structure changes after AKAP12 mutation.

[0057] Figure 7 B is the mass spectrometry molecular function enrichment map.

[0058] Figure 7 C is the result of AKAP12 and PKA co-IP.

[0059] Figure 7 D is the detection of PKA enzyme activity.

[0060] Figure 7 E: Immunofluorescence shows the distribution of PKA RII in neurons. DETAILED DESCRIPTION

[0061] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0062] Unless otherwise specified, the materials and reagents used in this example were obtained from commercial sources.

[0063] Example 1

[0064] In clinical work, the inventors discovered a child with autism and further sequenced and analyzed his genomic DNA, revealing a new frameshift mutation in his AKAP12 gene, c.1655-1659del.

[0065] Based on the above, the inventors constructed a rat autism animal model by knocking in the AKAP12 mutant gene according to the mutation site c.1655-1659del of the child using CRISPR / Cas9 technology; specifically, the following steps were included:

[0066] (1) Cas9 / gRNA target design

[0067] The nucleotide sequence of rat AKAP12 (NM_057103.2) gene was downloaded from the NCBI database, and homology comparison was performed. According to the mutation site c.1655-1659del of the child, the mutation site c.1655-1659del was determined on the homologous sequence of the rat. According to this site sequence, sgRNA sequences were designed, including sgRNA1 and sgRNA2, wherein the nucleotide sequence of sgRNA1 is 5'-GAGCTCTGCGTCGTCCCCCGAGG-3' (SEQ ID NO: 1), and the nucleotide sequence of sgRNA2 is 5'-GGTCTCCTCAGGCTCCTCGGGGG-3' (SEQ ID NO: 2).

[0068] (2) Construction of homologous recombination vector (Donor vector)

[0069] The homologous recombination vector Donor vector carries a mutation site, and its vector sequence is 5'-GAGAATACCAACACATTCACACCGAATCCCCAGAGAGTGCTGATGAGCAGAAGGG AGAGA(-----)GCGTCGTCGCCCGAGGAGCCTGAGGAGACCACGTGTCTGGAGAAA GGGCCGCTGGAAGCA -3' (SEQ ID NO: 3); wherein the horizontal line represents the frameshift mutation site c.1655-1659del.

[0070] (3) sgRNA in vitro transcription: After designing sgRNA according to the target sequence, construct an in vitro transcription vector sgRNA, expand it and culture it, extract the plasmid, and then digest it with DraⅠ and recover it on gel. Using the recovered product as a template, complete in vitro transcription with T7 RNA polymerase, and recover and purify the product on gel, and finally concentrate the product to 200ng / μl by ethanol precipitation. And mix it evenly with Cas9mRNA and Donor vector at a final concentration ratio of 200ng / μL:200ng / μL:200ng / μL, where the mass ratio of sgRNA1 to sgRNA2 is 1:1.

[0071] (4) Preparation of fertilized eggs: Select 3-4 week old SD female mice and inject them with pregnant mare serum (PMSG) and human chorionic gonadotropin (hCG) respectively, with an interval of 46-48 hours between the two. After the injection of HCG, mate the female mice with adult fertile male mice to fertilize them. The next day, euthanize the female mice, collect the fertilized eggs from the fallopian tubes, and place them in a constant temperature incubator of 37°C and 5% CO2 for later use.

[0072] (5) Pronuclear microinjection: prepare microinjection needles and fixing needles; add the prepared mRNA injection solution to the microinjection needle; select fertilized eggs with normal morphology and place them in an injection dish. Under an inverted microscope with a magnification of 200 to 400 times, inject the exogenous gene injection solution into the nucleus of the fertilized egg by microinjection; transfer the injected fertilized eggs to M16 culture medium and place them in a constant temperature 37°C 5% CO2 incubator for 0.5 to 1 hour before transplantation.

[0073] (6) Preparation of surrogate mice and embryo transplantation

[0074] Prepare pseudo-pregnant female mice: select fertile female mice of appropriate age and mate with male mice that have been sterilized after vasectomy to stimulate a series of pregnancy changes in the female mice to obtain pseudo-pregnant female mice, which will serve as surrogate mice after the genetically modified fertilized eggs; transplant the fertilized eggs that have been injected with foreign genes into the fallopian tubes of surrogate female mice on the day of thrombus formation; after the transplantation, place the surrogate female mice in a clean cage and keep them warm until they wake up and then return them to the cage for breeding; after a successful fallopian tube transplantation, the female mice will generally give birth 19-20 days after the operation; one week after the mice are born, their claws can be clipped and numbered, and PCR identification can be performed at the same time; three weeks after the mice are born, they can be raised independently in separate cages.

[0075] (7) Identification of F0 mice

[0076] Collect tissues (tail or toe tissues) from 1- to 2-week-old young mice; lyse the tissues and extract genomes;

[0077] PCR amplification and electrophoresis detection are performed using specific primers for the target gene to screen out offspring with the integration of the exogenous gene; mice with integration are called founder mice and can be passaged and established, and protein expression levels can be identified if necessary.

[0078] Among them, the specific primer sequences used for genotype identification of AKAP12 mutant gene knock-in rats include Rat

[0079] AKAP12-F (5'-CTGAAGAGAAGACGCTGCCCAAAC-3', SEQ ID NO:4) and Rat

[0080] AKAP12-R (5'-TATCCACCCTACGCTTTGGTTCCTC-3', SEQ ID NO: 5); the sequencing primer is sequence-F (5'-CAGAAGGCATTGTCAGTGAGGTG-3', SEQ ID NO: 6), the PCR amplification system is shown in Table 1, and the amplification program is shown in Table 2.

[0081] Filter results such as Figure 2As shown, after amplification, the wild-type sequence is 576 bp, and the mutant sequences are all 571 bp. The wild-type sequence is shown in SEQ ID NO: 7, and the AKAP12 mutant sequence is shown in SEQ ID NO: 8. The positive F0 rat obtained by screening is numbered #26.

[0082] Table 1 PCR amplification system

[0083] Reaction components Volume (μL) <![CDATA[2X Premix TaqddH2O]]> 10 <![CDATA[ddH2O]]> 8 Primer F 0.5 Primer R 0.5 DNA Template 1 Total 20

[0084] Table 2 PCR amplification program

[0085]

[0086] SEQ ID NO:7(WT PCR product):576bp

[0087] ;

[0088] SEQ ID NO:8 (Mutant PCR product): 571bp

[0089] ctgaagagaagacgctgcccaaacacccagaaggcattgtcagtgaggtggagatgctgtcctctcaggaaagaatcaaggt acagggaagtcccttgaagaaactcttcagtagctcaggcttaaagaagctgtctgggaagaagcagaaggggaaacgaggaggtg ggggagacgaagagcctggagaataccaacacattcacaccgaatccccagagagtgctgatgagcagaagggagaga-----gc gtcg tcg cccgaggagcctgaggagaccacgtgtctggagaaagggccgctggaagcaccccaggatggggaagctgaggaaggaactacttccgatggagagaagaagagggaagggatcactccctgggcatccttcaaaaagatggtgacacccaagaaacgggtccgaagaccttctgagagtgacaaggaggaagagctggagaaggtcaagagcgccaccttgtcctccactgatagcacagtgtcagaaatgcaagatgaagtcaaaactgttggtgaggaacaaaagccagaggaaccaaagcgtagggtggata, among which, the horizontal line indicates the frameshift mutation site c.1655-1659del, and the underline indicates the silent mutation tcc>tcg.

[0090] (8) The positive F0 generation rats grown to 8 weeks old were mated with wild-type rats of the opposite sex to obtain F1 generation rats, and tail blood was collected for PCR amplification identification (the detailed process is the same as step (3)) to obtain F1 generation heterozygous rats. The F1 generation heterozygous rats grown to 8 weeks old were further crossed to obtain F2 generation rats, and tail blood was collected for PCR amplification identification (same as above) to obtain positive F2 generation homozygous rats, namely AKAP12 mutant gene knock-in rats (AKAP12 mutant rats), and the AKAP12 mutant gene knock-in rat autism animal model was constructed ( Figure 1 ).

[0091] Effect Example

[0092] 1. Ultrasonic sound test for mother-child separation

[0093] On the 2nd, 4th, 6th, 8th, 10th, 12th and 14th day after birth, the pups were separated from their mothers one by one and placed in a special soundproof test box for a 5-minute ultrasonic vocalization test. By the 14th day after birth, the pups began to open their eyes and the number of times they looked for their mothers decreased significantly, so the data was only recorded up to the 14th day after birth.

[0094] The results of ultrasonic vocalization tests showed that from the second day after birth (P2) to the 12th day after birth (P12), the total duration of vocalization of the two groups of rats gradually increased with the number of days after the pups were separated from their mothers, and reached a peak at P12 ( Figure 3 A). The number of vocalizations recorded by the instrument in both groups of rats gradually increased with the passage of days and reached a peak at P12 ( Figure 3 B). Figure 3 C represents the ultrasonic wave graph, and the vertical yellow line is the spectrum of rat vocalizations after screening at a specific frequency. It can be visually observed that the sound wave density of different frequencies represented by the vertical yellow line in the WT group is significantly higher than that in the HO group. Clinically, after being separated from their mothers in a specific environment, the children search for their mothers less often than normal children of the same age, which is consistent with the phenotype of the rat model in this experiment.

[0095] 2. Three-box social test and social behavior analysis

[0096] Three-box social interaction: The experimental rats were pre-pacified one week before the experiment, for 10 minutes per rat per day, to eliminate the influence of anxiety and fear caused by the experimental operator's grasping and smell during the experiment on the experimental results.

[0097] On the day of the experiment, the experimental mice were first placed in three boxes and allowed to freely explore the familiar box environment for 10 minutes; then, a strange wild-type rat Stranger1 (S1) of the same age and gender was placed in box A. At this time, cage B was empty, and the activities of the experimental mice in the three boxes were tracked and recorded for 10 minutes; then, a strange wild-type rat Stranger2 (S2) of the same age and gender was added to cage B, and the activities of the experimental mice in the three boxes were tracked and recorded for 10 minutes.

[0098] In the social interaction test, when choosing between an empty cage (E) and a living cage (S1), the WT group stayed in the S1 cage for 256.6 seconds and in the E cage for 95.74 seconds, p < 0.0001; the HO group stayed in the S1 cage for 105.83 seconds and in the E cage for 24.22 seconds, p < 0.0001 ( Figure 4 A). Both groups of rats showed a preference for interacting with the stranger rat S1, indicating no significant difference in sociability.

[0099] In the novelty preference test, the stranger mouse S1 has become a familiar communication partner to the experimental mouse after the previous stage of communication. The stranger mouse S2 that is introduced at this time is completely unfamiliar to the experimental mouse. Figure 4 As shown in B, after the stranger mouse S2 was placed, the WT group stayed in the S1 cage for 117.42 s and in the S2 cage for 200.42 s, p < 0.0001. The time the WT group rats interacted with S2 was significantly more than that with S1, showing a certain "novelty-loving, old-disliking" phenotype.

[0100] Social behavior analysis: Experimental mice and wild-type mice of the same age and sex were placed in an open box and allowed to interact for 10 minutes and recorded. By analyzing the video, the interaction between the experimental and control mice was observed, including the number of times the experimental mice chased the control mice, the number of times the experimental mice sniffed the control mice's anus, the number of times the two pushed each other, and the number of times the experimental mice groomed their fur, and the statistics were made.

[0101] The results are as follows Figure 4 As shown in C, when interacting with rats of the same age and sex, the HO group had significantly fewer sniffing and pushing times, which were 9.45 and 10.36 times, respectively, while the WT group had 13.5 and 14.2 times, respectively. There was no difference between WT and HO in the following action, which was 10.1 and 8 times, respectively.

[0102] 3. Analysis of stereotyped behaviors of bead burying and grooming

[0103] The bead burying test and grooming behavior analysis are commonly used methods to detect stereotyped phenotypes in rodent models of ASD. The bead burying test involves taking rats out of their cages, laying 5 cm of bedding in a 45 cm × 23 cm × 20 cm rat cage, and placing marbles in the cage in 4 rows of 4 equal distances; the rats are placed in the center of the cage and allowed to move freely for 10 minutes without any food or water. After the test, the rats are returned to their original cages, and the number of marbles buried by the rats is recorded. The marbles are considered buried if at least 2 / 3 of the marbles are submerged in the bedding. After each group of rats is tested, new bedding is required, and the marbles are cleaned and wiped with alcohol to avoid the influence of residual odors from the previous batch of rats on subsequent rat experiments. After the end of the bead burying test, the number of buried beads is counted.

[0104] The results are as follows Figure 5 As shown in A, the average number of buried beads in the WT group was 3.97, and that in the HO group was 6.5. After statistical analysis, p = 0.0043, indicating that the number of buried beads in the HO group was significantly greater than that in the WT group.

[0105] The grooming behavior of rats can be divided into two categories: rostral grooming, which involves rubbing movements of the front paws toward the nose, face, head, and ears; and body grooming, which involves cleaning the ventrolateral area of ​​the trunk, the anogenital area, and the tail with the paws and mouth. The grooming behavior of rats was analyzed by videotaping and the number of times was counted. Figure 5 As shown in B, within the specified time, the average number of grooming times in the WT group was 9.5 times, and that in the HO group was 12.9 times. After statistical analysis, p = 0.0194, and the number of grooming times in the HO group was significantly higher than that in the WT group.

[0106] The above behavioral tests show that AKAP12 gene mutation knock-in rats can well reproduce the typical clinical manifestations of social disorders and repetitive stereotyped behaviors of autistic patients, and can be used as an autism mouse model.

[0107] 4. Map2 mRNA level increased and protein level decreased in AKAP12 mutant mice

[0108] Map2 plays an important role in neuronal morphogenesis and dendrite formation, and the loss of Map2 may be the endophenotype that characterizes autism spectrum disorders, especially in terms of synaptic plasticity. In postmortem brain tissue of autistic patients, the lack of Map2-mediated activity-dependent dendritic spine growth leads to a shift in dendritic spine morphology to a more immature phenotype. Therefore, the abundance and function of Map2 are very important in autism models.

[0109] The present invention detected the expression of Map2 at the transcriptional and translational levels in AKAP12 mutant mice. Figure 6 As shown in A, the mRNA level of Map2 increased significantly by 3.01 times, while the protein level decreased by 0.74 times ( Figure 6 B, C). The results suggest that Map2 protein may have reduced translation or increased degradation, thereby feedback regulation to increase mRNA synthesis.

[0110] 5. After mutation, the PKA binding domain of AKAP12 is lost, resulting in reduced PKA activity

[0111] The PKA signaling pathway and the G protein signaling pathway are involved in neuronal function, gene expression, memory, and cell differentiation. It has been found that the activity of PKA in the brain of autism models is significantly reduced, and PKA can also be used as an important indicator for diagnosing the phenotype of autistic patients. AKAP12 belongs to the A-kinase anchor proteins (AKAPs) family and is a regulatory molecule of protein kinase A (PKA). It can form a complex with the latter and is highly expressed on nerve cells, activating the cAMP-dependent PKA signaling pathway and the G protein signaling pathway. After AKAP12 mutation, a truncated protein with a length of about 1 / 3 of the wild type is produced. Combined with the enrichment analysis of the protein spectrum results, the truncated protein may have a missing C-terminal PKA binding domain ( Figure 7 A, B). Co-IP verification showed that the PKA binding domain of AKAP12 was lost after mutation ( Figure 7 C). After the PKA binding domain of AKAP12 protein is lost, it cannot provide a scaffold for the activation of PKA. Through PKA activity detection, after the AKAP12 gene mutation caused the loss of PKA binding domain, the activity of PKA decreased by 0.61 times ( Figure 7 D). Immunofluorescence confirmed that PKA RII is mainly distributed in dendrites in primary neurons ( Figure 7 E).

[0112] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A sgRNA specifically targeting an AKAP12 mutant gene, wherein the sequence of the sgRNA comprises: sgRNA1:GAGCTCTGCGTCGTCCCCCGAGG; and / or, sgRNA2:GGTCTCCTCAGGCCTCGGGGG.

2. A kit comprising the sgRNA according to claim 1.

3. The kit according to claim 2, characterized in that The kit also includes Cas9 mRNA and / or a homologous vector containing a mutation site, wherein the mutation site is c.1655-1659del; preferably, the nucleotide sequence of the homologous vector containing the mutation site is as shown in SEQ ID NO:

3.

4. The kit according to any one of claims 2 to 3, characterized in that The kit further comprises amplification primers and sequencing primers; preferably, the amplification primers comprise a primer pair shown in SEQ ID NO:4 and SEQ ID NO:5; preferably, the sequence of the sequencing primers is shown in SEQ ID NO:

6.

5. Use of the sgRNA according to claim 1 or the kit according to any one of claims 2 to 4 in constructing an AKAP12 mutant gene knock-in animal model.

6. The use according to claim 5, characterized in that: The animal models include mice, rats, and monkeys.

7. A method for constructing an AKAP12 mutant gene knock-in animal model, characterized in that: The method comprises constructing the kit using any one of claims 2 to 4.

8. The method according to claim 7, characterized in that The method comprises: introducing a mixture of the Cas9 mRNA, the homologous vector and the sgRNA into a fertilized egg of a model animal, obtaining a viable fertilized egg, transplanting the egg into a surrogate mother, breeding, obtaining offspring and performing genotype identification and screening.

9. The method according to claim 8, characterized in that The mass ratio of the Cas9 mRNA, the homologous vector and the sgRNA is 1:0.5-1.5:0.5-1.5; preferably, the mass ratio of the gRNA1 and the sgRNA2 is 1:0.5-1.

5.

10. Use of the AKAP12 mutant gene knock-in animal model constructed by the method according to any one of claims 7 to 9 in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.